Li, Bob T.

Publications

Sort by

Co-Author Network

selected publications

Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply. The New England journal of medicine. 2022 Letter GET IT
Times cited: 1
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature medicine. 2022 Academic Article GET IT
Times cited: 5
Inferring gene expression from cell-free DNA fragmentation profiles. Nature biotechnology. 2022 Academic Article GET IT
Times cited: 24
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer treatment reviews. 2022 Review GET IT
Times cited: 25
Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO precision oncology. 2022 Review GET IT
Times cited: 16
Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers. British journal of cancer. 2021 Academic Article GET IT
Times cited: 5
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid Biopsies. The Journal of molecular diagnostics : JMD. 2021 Academic Article GET IT
Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021 Academic Article GET IT
Times cited: 88
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 11
Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 Academic Article GET IT
Times cited: 11
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]. Lung cancer (Amsterdam, Netherlands). 2021 Article GET IT
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. The New England journal of medicine. 2021 Academic Article GET IT
Times cited: 208
The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer. Cancers. 2021 Review GET IT
Times cited: 4
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung cancer (Amsterdam, Netherlands). 2021 Academic Article GET IT
Times cited: 12
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature communications. 2021 Academic Article GET IT
Times cited: 42
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. Ophthalmology. Retina. 2021 Academic Article GET IT
Times cited: 3
Sotorasib for Lung Cancers with KRAS p.G12C Mutation. The New England journal of medicine. 2021 Academic Article GET IT
Times cited: 500
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome medicine. 2021 Academic Article GET IT
Times cited: 14
The emerging role of local therapy in oligometastatic non-small cell lung cancer. The Journal of thoracic and cardiovascular surgery. 2021 Editorial Article GET IT
Times cited: 3
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 30
Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm. Chest. 2021 Academic Article GET IT
Times cited: 9
KRAS ^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 13
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021 Academic Article GET IT
Times cited: 16
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA surgery. 2021 Academic Article GET IT
Times cited: 35
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO precision oncology. 2021 Academic Article GET IT
Times cited: 3
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Investigational new drugs. 2021 Academic Article GET IT
Times cited: 5
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Editorial Article GET IT
Times cited: 3
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 24
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. 2020 GET IT
Times cited: 63
KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 744
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. 2020 Academic Article GET IT
Times cited: 4
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 9
ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The oncologist. 2020 Academic Article GET IT
Times cited: 6
COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 152
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer. Cancer discovery. 2020 Academic Article GET IT
Times cited: 168
Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 26
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 100
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer discovery. 2020 Academic Article GET IT
Times cited: 164
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature cancer. 2020 Academic Article GET IT
Times cited: 72
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 57
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature medicine. 2019 Academic Article GET IT
Times cited: 366
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 125
Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 25
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer. 2019 Academic Article GET IT
Times cited: 38
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta oncologica (Stockholm, Sweden). 2019 Academic Article GET IT
Times cited: 7
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 20
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 69
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 79
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 78
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 32
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 98
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2019 Academic Article GET IT
Times cited: 6
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 64
Liquid biopsy guided precision therapy for lung cancers. Journal of thoracic disease. 2018 Editorial Article GET IT
Times cited: 620
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 176
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer cell. 2018 Academic Article GET IT
Times cited: 465
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 72
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 79
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 200
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Therapeutics and clinical risk management. 2018 Review GET IT
Times cited: 73
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Academic Article GET IT
Times cited: 99
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 300
CT features of HER2-mutant lung adenocarcinomas. Clinical imaging. 2018 Review GET IT
Times cited: 7
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies. Cancer chemotherapy and pharmacology. 2018 Academic Article GET IT
Times cited: 17
Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer. The Journal of thoracic and cardiovascular surgery. 2018 Editorial Article GET IT
Times cited: 8
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 164
HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Academic Article GET IT
Times cited: 473
Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 191
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer discovery. 2017 Academic Article GET IT
Times cited: 234
Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. Annals of translational medicine. 2017 Comment GET IT
Times cited: 45
Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. 2017 GET IT
Times cited: 21
Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. Asia-Pacific journal of clinical oncology. 2017 Academic Article GET IT
Times cited: 9
Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Advances in radiation oncology. 2017 Academic Article GET IT
Times cited: 30
An approach to suppress the evolution of resistance in BRAF^V600E-mutant cancer. Nature medicine. 2017 Academic Article GET IT
Times cited: 107
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. The Cochrane database of systematic reviews. 2017 Review GET IT
Times cited: 11
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 399
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of oncology. 2017 Review GET IT
Times cited: 293
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 10
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology. 2016 Academic Article GET IT
Times cited: 52
The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung cancer (Amsterdam, Netherlands). 2016 Review GET IT
Times cited: 10
Chemotherapy remains an essential element of personalized care for persons with lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Review GET IT
Times cited: 69
PET monitoring of liver directed selective internal radionuclide therapy for metastatic gastro-oesophageal cancer. 2016 GET IT
Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PloS one. 2016 Review GET IT
Times cited: 16
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. Lung cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 40
What does the future hold for immunotherapy in cancer?. Annals of translational medicine. 2016 Academic Article GET IT
Times cited: 4578
Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. Neuroendocrinology. 2016 Review GET IT
Times cited: 10
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. PloS one. 2016 Academic Article GET IT
Times cited: 15
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Academic Article GET IT
Times cited: 182
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. 2015 GET IT
Times cited: 34
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 47
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 966
Measurement of preoperative lobar lung function with computed tomography ventilation imaging: progress towards rapid stratification of lung cancer lobectomy patients with abnormal lung function. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2015 Academic Article GET IT
Times cited: 21
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Academic Article GET IT
Times cited: 225
Pathogenic PALB2 mutation in metastatic pancreatic adenocarcinoma and neuroendocrine tumour: A case report. Molecular and clinical oncology. 2015 Academic Article GET IT
Times cited: 36
Dramatic response to selective internal radiation therapy for unresectable hepatocellular carcinoma. Oxford medical case reports. 2015 Academic Article GET IT
Localized malignant pleural mesothelioma with renal metastasis. 2015 GET IT
Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy. Journal of clinical medicine. 2014 Academic Article GET IT
Times cited: 34
Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World journal of gastrointestinal pathophysiology. 2014 Review GET IT
Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. Oxford medical case reports. 2014 Academic Article GET IT
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. Journal of clinical medicine. 2014 Review GET IT
Times cited: 243
Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. World journal of oncology. 2013 Academic Article GET IT
Times cited: 141

more ...

less ...

Background

education and training

Ph.D., University of Sydney (Australia) 2021
M.D., University of the State of New York 2016
M.P.H., University of Sydney (Australia) 2014
B.Sc., University of New South Wales School of Medicine (Australia) 2006
M.B.,B.S., University of New South Wales School of Medicine (Australia) 2006

Contact

full name

Bob T. Li

VIVO Weill Cornell Medical College

Bob T. Li Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name